---
title: "NUCLEOME THERAPEUTICS LIMITED — Ownership Dossier"
canonical: https://whiteintel.dev/entity/0ef94385-c561-5d7a-92cb-8f85b51ef167
json: https://whiteintel.dev/api/public/dossier/0ef94385-c561-5d7a-92cb-8f85b51ef167
identifier: oo:GB-COH-12109297
jurisdiction: GB
risk: Low
source: WhiteIntel corporate-ownership graph
---

# NUCLEOME THERAPEUTICS LIMITED

**Type:** Company  
**Jurisdiction:** [GB](https://whiteintel.dev/jurisdictions/gb)  
**Identifier:** `oo:GB-COH-12109297`  
**Risk level:** Low  
**Canonical dossier:** https://whiteintel.dev/entity/0ef94385-c561-5d7a-92cb-8f85b51ef167  
**Structured JSON / MCP:** https://whiteintel.dev/api/public/dossier/0ef94385-c561-5d7a-92cb-8f85b51ef167  

## Ownership & control

### Owners / controllers

- **James Raymond Hughes** (beneficial owner) — 100% — https://whiteintel.dev/entity/d89e4f54-c157-521b-98d9-2060b8e65be0
- **OXFORD SCIENCE ENTERPRISES PLC** (beneficial owner) — 50% — https://whiteintel.dev/entity/23368d2b-9696-5261-8a95-3dcac8b35a88
- **James Raymond Hughes** (beneficial owner) — 87.5% — https://whiteintel.dev/entity/64593810-1128-42ba-a74b-232217e15550
- **OXFORD SCIENCE ENTERPRISES PLC** (beneficial owner) — https://whiteintel.dev/entity/23368d2b-9696-5261-8a95-3dcac8b35a88

### UBO chain (walk to the ultimate owner)

A **4-step** ownership/control chain to the ultimate beneficial owner is resolved for this entity. The full cited chain unlocks with a paid API key or a one-off dossier — https://whiteintel.dev/pricing.

## Company profile (live · UK Companies House)

- **Company number:** `12109297`
- **Status:** active
- **Type:** ltd
- **Incorporated:** 2019-07-17
- **Registered office:** Nucleome Therapeutics Limited, Inventa, Botley Road, Oxford, OX2 0HA, United Kingdom
- **SIC:** 72110

### Officers

- AL-HALLAQ, Rana Abdul Raouf, Dr — director · American · appointed 2022-10-21
- ANNINGA, Bauke, Dr — director · Dutch · appointed 2022-10-21
- BODMER, Mark — director · British · appointed 2024-07-24
- DAVIS, John — director · American · appointed 2024-02-15
- GREIG, Russell George, Dr — director · American,British · appointed 2023-09-06
- HEPPLE, Jonathan Paul, Dr — director · British · appointed 2020-11-30
- HUGHES, James Raymond — director · British,Irish · appointed 2019-07-17
- ISHNAZAROVA, Nadiya, Dr — director · Russian · appointed 2025-12-04
- BOYD, Phil — secretary · appointed 2022-10-21 · resigned 2024-07-26
- JEZIORSKA, Danuta Mariola, Dr — director · Polish,British · appointed 2019-08-02 · resigned 2024-04-19
- JOHNSON, Emma — director · British · appointed 2023-03-02 · resigned 2025-12-04
- MACKINNON, Lachlan Tom — director · British · appointed 2019-08-02 · resigned 2020-10-16
- MACLAUGHLIN, Fiona Caroline, Dr — director · British · appointed 2022-10-21 · resigned 2025-12-04

### Beneficial owners (Persons with Significant Control)

- [Oxford Science Enterprises Plc](https://whiteintel.dev/entity/23368d2b-9696-5261-8a95-3dcac8b35a88) — 25–50% votes · corporate PSC · United Kingdom — since 2019-08-02
- James Raymond Hughes — 75–100% shares · individual PSC · United Kingdom — ceased 2019-07-29

## Provenance

- OpenOwnership — https://find-and-update.company-information.service.gov.uk/company/12109297
- companies_house_bulk — https://find-and-update.company-information.service.gov.uk/company/12109297

---

_This is the markdown-for-agents view of the WhiteIntel dossier for **NUCLEOME THERAPEUTICS LIMITED**. Human view: https://whiteintel.dev/entity/0ef94385-c561-5d7a-92cb-8f85b51ef167 · Structured JSON: https://whiteintel.dev/api/public/dossier/0ef94385-c561-5d7a-92cb-8f85b51ef167._

_Risk levels are heuristic investigative leads, not legal determinations of beneficial ownership. Every claim carries a source; an absent edge means "not yet observed in current sources", not "does not exist"._